4D Molecular Therapeutics reports Q1 results today with short sellers holding one of the heaviest positions in the biotech space.
Short interest has climbed sharply into the print. At 20.7% of the free float — up 18% over the past month and 4.6% over the past week — the short position ranks in just the 11th percentile of the broader universe on the short score ranking, meaning shorts are more concentrated here than in nearly 90% of comparable names. The ORTEX short score has held above 70 for several sessions, consistent with elevated bearish pressure. Borrow costs remain near-negligible at 0.54%, and availability is wide — well above the levels that would signal a squeeze risk — which means the lending market offers no structural impediment to further shorting if bears choose to press.
Options positioning, however, is not particularly charged. The put/call ratio runs at 0.48, only marginally above its 20-day average of 0.43 and well within one standard deviation of normal. That gap between a heavy short position and a calm options market is notable: bears are expressing their view through stock borrows rather than through downside hedging in derivatives. The stock itself has recovered 12% on the week after falling roughly 5% on Thursday alone, closing at $9.93. That weekly bounce partially offsets a flat month.
The analyst community is uniformly bullish on direction but scattered on conviction. All recent coverage carries Buy or Outperform ratings, yet targets range from $21 to $36. Jefferies, which assumed coverage in late March, set its target at $21 — roughly half the levels that RBC Capital and HC Wainwright maintain — a signal that at least one firm sees materially higher execution risk ahead. The mean target of $28.78 implies more than 190% upside from current levels, a gap that reflects how far the stock has fallen from where analysts originally modelled it. On the bull side, the case rests on the depth of the pipeline across ophthalmology, cardiology, and pulmonology, and the differentiation of 4D-MT's gene therapy delivery platform. Bears point to the absence of a clear dose-dependent efficacy signal in key trials, the pre-revenue nature of the business, and the near-certainty of future dilutive financing.
Institutional ownership shows some genuine conviction among specialist investors. RA Capital and BVF Partners — two of biotech's most sophisticated long-only funds — hold a combined 20% of shares. Novo Holdings added 1.65 million shares as recently as year-end. That depth of specialist ownership adds a floor beneath sentiment, but it also means the register is already well-informed: today's print is less likely to be a surprise for those holders than for the broader market.
The Q1 report arrives as the central question for the stock — whether any 4D-MT programme can deliver clean, reproducible efficacy data — meets 20% short interest and a stock trading at a fraction of where analysts expect it to be.
See the live data behind this article on ORTEX.
Open FDMT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
